Phase 4 N=46 Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Benign Prostatic Hyperplasia (BPH)
Primary: Post-void Residual (PVR) Volume — 101.7; 75.8 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants
Phase 2 N=16 Effects of Varenicline on Cigarette Self Administration
Nicotine Dependence
Primary: Cigarette Choice — 3.67; 3.17; 2.83; 2.83 number of cigarette choices (0-9)
Phase 2 N=124 Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
Gastric Cancer
Primary: Progression Free Survival (PFS) in the Overall Study Population — 3.91; 3.55 months
Phase 4 N=63 Oral Dexamethasone for Treatment of Migraine
Migraine
Primary: Proportion of Patients Who Were Discharged Pain Free That Have a Recurrence of Headache Within 48 Hours. — 13; 14 Participants
Phase 2 N=45 Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Determine the Antitumor Activity of Gemcitabine/Carboplatin/Bevacizumab Regimen as Measured by the Probability of Surviving Progression-free for at Least 6 Months or…
Phase 2 N=12 Interferon Gamma-1b in Friedreich Ataxia (FRDA)
Friedreich Ataxia
Primary: Change in Whole Blood Frataxin Levels — -1.5 percentage of baseline frataxin level — p=0.027
N/A N=12 Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
Type 1 Diabetes Mellitus
Primary: Assess Difference in Hepatic Glycogen Measured in the Fasting State Before vs. After Repeated Glucagon Administration — 6.5 g/L
Phase 2 N=21 Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Lung Adenocarcinoma
Primary: The Maximum Tolerated Dose (MTD) of Cetuximab Given Every 2 Weeks — 500; 500; 500 mg/m2 of CETUXIMAB
N/A N=40 Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®
Pharmacokinetics
Primary: Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol — 1275; 1240; 21.9; 14.8 ng/L
N/A N=80 Custom Molded Foot Orthoses Effect on Foot Kinematics and Lower Extremity Electromyography During Walking and Running.
Lower Extremity Pain of a Mechanical Origin
Primary: Maximum Rearfoot Eversion Motion During Stance — 1.1; 1.1; 2.9; 3.0 Degrees — p=> .10
Phase 2 N=46 Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)
Chorioamnionitis · Brain Injury
Primary: NAC Terminal Elimination Half-life — 1.2; 7.5; 5.1 hours
Phase 2 N=51 A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery
Acute Pain
Primary: Summed Pain Intensity Differences Over 24 Hours (SPID 0-24) Following the Initial Administration of Study Drug — -52.08; -292.7 units on a scale * hours — p=<0.05
N/A N=396 Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)
Pregnancy · Neonates
Primary: Percentage of Women With ≥1 Live Born Infant During Follow-up (Take-Home Baby Rate) — 23.5; 34.4 Percentage of participants
Phase 4 N=167 Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Fuchs' Dystrophy · Corneal Edema
Primary: Intraocular Pressure — 11; 27 eyes